Vaxcyte reported a net loss for the third quarter of 2026 as it accelerated clinical development and manufacturing scale-up for its lead vaccine candidate, VAX-31. Following successful topline results from its pivotal Phase 3 OPUS-1 trial, the company significantly strengthened its liquidity position through concurrent equity and debt offerings.

Key Highlights

  • VAX-31 achieved all primary endpoints in the OPUS-1 Phase 3 trial, demonstrating noninferiority to PCV20 and PCV21 across shared serotypes and superiority in unique serotypes.
  • Pro forma cash equivalents and investments reached approximately $3.4 billion, including $1.1 billion in net proceeds from October 2026 financing activities.
  • Research and development expenses increased to $270.3 million from $209.9 million year-over-year, primarily due to OPUS Phase 3 trial costs and commercial manufacturing preparations.